サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1785842

バイオマーカー探索アウトソーシングサービスの世界市場

Biomarker Discovery Outsourcing Services

出版日
ページ情報
英文 216 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
バイオマーカー探索アウトソーシングサービスの世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 216 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

バイオマーカー探索アウトソーシングサービスの世界市場は2030年までに519億米ドルに達する見込み

2024年に165億米ドルと推定されるバイオマーカー探索アウトソーシングサービスの世界市場は、2024～2030年の分析期間にCAGR 21.0％で成長し、2030年には519億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるサロゲートエンドポイントは、CAGR 22.2%を記録し、分析期間終了までに228億米ドルに達すると予測されます。予測バイオマーカー分野の成長率は、分析期間のCAGRで19.6％と推定されます。

米国市場は43億米ドルと推定、中国はCAGR19.9%で成長予測

米国のバイオマーカー探索アウトソーシングサービス市場は、2024年に43億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに79億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.4％と18.0％と予測されています。欧州では、ドイツがCAGR約14.3%で成長すると予測されています。

世界のバイオマーカー探索アウトソーシングサービス市場- 主要動向と促進要因のまとめ

バイオマーカー探索のアウトソーシングが医薬品開発にとって重要な戦略になりつつあるのはなぜか？

バイオマーカー探索は、製薬企業やバイオテクノロジー企業が薬効を高め、患者選択を改善し、規制当局の承認を早めることを可能にする、現代の医薬品開発において極めて重要な要素となっています。バイオマーカー調査の複雑さとコストが増大していることから、多くの企業は業務の合理化、財務的負担の軽減、専門知識の活用のために、アウトソーシング・パートナーに目を向けています。医薬品開発業務受託機関（CRO）やバイオマーカー探索の専門企業は、標的同定、バリデーション、バイオインフォマティクス解析、薬事サポートを含むエンドツーエンドのサービスを提供し、製薬企業は中核的な研究や商業化戦略に集中することができます。精密医療やコンパニオン診断に対する需要の急増は、バイオマーカー探索のアウトソーシングの必要性をさらに高めています。治療効果を予測するためのバイオマーカーへの依存度が高まる中、アウトソーシングパートナーはバイオマーカーアッセイの開発とバリデーションにおいて重要なサポートを提供しています。さらに、がん、心血管疾患、自己免疫疾患などの慢性疾患の増加により、革新的なバイオマーカーの必要性が高まっており、製薬会社は最先端の技術や規制上のノウハウを持つ外部の研究機関と協力するようになっています。

技術の進歩はバイオマーカー探索のアウトソーシングをどのように変えるのか？

次世代シーケンサー（NGS）、プロテオミクス、メタボロミクスの急速な進化により、バイオマーカー探索の状況は大きく変わりつつあり、疾患特異的な分子シグネチャーをより正確かつ効率的に同定できるようになっています。人工知能（AI）と機械学習はデータ解析に革命をもたらし、研究者は以前は検出できなかったバイオマーカー相関を発見し、臨床試験における患者の層別化を改善することができます。これらの先端技術は、アウトソーシング・サービス・プロバイダーがバイオマーカーの同定、検証、予測モデリングを強化し、医薬品開発のタイムラインとコストを大幅に削減するのに役立っています。さらに、バイオインフォマティクスと計算生物学の進歩により、開発業務受託機関はより包括的なバイオマーカー探索サービスを提供できるようになっています。ハイスループットスクリーニング、シングルセル解析、マルチオミクスアプローチはバイオマーカー調査範囲を拡大し、疾患メカニズムのより正確な理解を確実なものにしています。さらに、非侵襲的なバイオマーカー検出を可能にするリキッドバイオプシー技術の台頭が、バイオマーカー探索のアウトソーシングサービスに浸透しつつあり、リアルタイムの疾患モニタリングと早期発見に新たな道を提供しています。こうした技術が進化を続ける中、バイオマーカー主導の医薬品開発を加速させようとする製薬企業にとって、アウトソーシング・パートナーはますます不可欠な存在となっています。

バイオマーカー探索アウトソーシングの成長を促す市場動向とは？

バイオマーカー探索のアウトソーシングを促進する最も重要な動向の1つは、個別化医療の重視の高まりです。ヘルスケアがオーダーメイドの治療戦略にシフトする中、製薬会社はアウトソーシングサービスを活用して、患者の正確な層別化と標的治療を可能にするバイオマーカーを開発しています。この動向は特にがん領域で顕著であり、免疫療法や標的がん治療においてバイオマーカー主導の医薬品開発が極めて重要な役割を果たしています。もう一つの大きな動向は、創薬のタイムラインを加速させるために、製薬会社と医薬品開発業務受託機関（CRO）との連携が進んでいることです。バイオマーカー探索をアウトソーシングすることで、医薬品開発企業は社内に大規模な投資をすることなく、最先端の技術や専門知識を利用することができます。さらに、FDAやEMAなどの規制当局がバイオマーカー主導の医薬品承認を重視していることも、製薬企業がバイオマーカーの検証やコンプライアンスサポートをアウトソーシングするインセンティブとなっています。分散型臨床試験やバーチャル臨床試験の台頭も、遠隔バイオマーカー収集やAIを活用したデータ解析が普及するにつれて、バイオマーカー探索の状況を変えつつあります。

バイオマーカー探索アウトソーシング市場の主な成長促進要因は？

バイオマーカー探索アウトソーシングサービス市場の成長は、バイオマーカー研究の複雑化、精密医療に対する需要の高まり、AIを活用したデータ分析の進歩など、いくつかの要因によってもたらされます。自社でのバイオマーカー探索にかかるコストが高いことから、製薬会社は費用対効果が高く効率的なバイオマーカー・ソリューションを提供できる外部パートナーを求めるようになっています。また、アウトソーシングによって医薬品開発企業が多様な患者集団にまたがる試験を実施できるようになるため、臨床試験の世界化と多地域にわたるバイオマーカー検証試験の必要性も市場開拓に寄与しています。さらに、ビッグデータ解析とクラウドベースのプラットフォームの統合により、バイオマーカー探索のワークフローが合理化され、データ解釈が改善され、臨床試験の成功率が向上しています。バイオマーカー主導型治療薬への需要が拡大し続ける中、アウトソーシングは医薬品開発を加速させ、個別化医療を推進する上でますます重要な役割を果たすようになると予想されます。

セグメント

種類（代替エンドポイント、予測バイオマーカー、予後バイオマーカー、安全性バイオマーカー）、探索段階（バイオマーカー同定段階、バイオマーカー検証段階、バイオマーカープロファイリング段階、バイオマーカーパネル開発段階、バイオマーカー選択段階）、治療領域（がん治療領域、循環器治療領域、神経治療領域、自己免疫疾患治療領域、その他の治療領域）、エンドユーザー（バイオテクノロジー企業エンドユーザー、製薬企業エンドユーザー、その他のエンドユーザー）

調査対象企業の例

  • AB Sciex LLC
  • BioIVT LLC
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Crown Bioscience Inc.
  • Discovery Life Sciences
  • Eurofins Scientific SE
  • Evotec SE
  • Laboratory Corporation of America Holdings
  • Metabolon, Inc.
  • REPROCELL Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29592

Global Biomarker Discovery Outsourcing Services Market to Reach US$51.9 Billion by 2030

The global market for Biomarker Discovery Outsourcing Services estimated at US$16.5 Billion in the year 2024, is expected to reach US$51.9 Billion by 2030, growing at a CAGR of 21.0% over the analysis period 2024-2030. Surrogate Endpoints, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$22.8 Billion by the end of the analysis period. Growth in the Predictive Biomarkers segment is estimated at 19.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.3 Billion While China is Forecast to Grow at 19.9% CAGR

The Biomarker Discovery Outsourcing Services market in the U.S. is estimated at US$4.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$7.9 Billion by the year 2030 trailing a CAGR of 19.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Biomarker Discovery Outsourcing Services Market - Key Trends & Drivers Summarized

Why Is Biomarker Discovery Outsourcing Becoming a Critical Strategy for Drug Development?

Biomarker discovery has become a crucial element in modern drug development, enabling pharmaceutical and biotech companies to enhance drug efficacy, improve patient selection, and accelerate regulatory approvals. Given the growing complexity and cost of biomarker research, many companies are turning to outsourcing partners to streamline operations, reduce financial burdens, and leverage specialized expertise. Contract research organizations (CROs) and specialized biomarker discovery firms offer end-to-end services, including target identification, validation, bioinformatics analysis, and regulatory support, allowing pharmaceutical firms to focus on core research and commercialization strategies. The surge in demand for precision medicine and companion diagnostics has further fueled the need for biomarker discovery outsourcing. As drug developers increasingly rely on biomarkers to predict therapeutic responses, outsourcing partners are providing critical support in biomarker assay development and validation. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and autoimmune conditions has intensified the need for innovative biomarkers, prompting pharmaceutical companies to collaborate with external research organizations that have cutting-edge technologies and regulatory know-how.

How Are Technological Advancements Transforming Biomarker Discovery Outsourcing?

The rapid evolution of next-generation sequencing (NGS), proteomics, and metabolomics is reshaping the biomarker discovery landscape, enabling more precise and efficient identification of disease-specific molecular signatures. Artificial intelligence (AI) and machine learning are revolutionizing data analysis, allowing researchers to uncover previously undetectable biomarker correlations and improve patient stratification in clinical trials. These advanced technologies are helping outsourcing service providers enhance biomarker identification, validation, and predictive modeling, significantly reducing drug development timelines and costs. Furthermore, advances in bioinformatics and computational biology are enabling contract research organizations to provide more comprehensive biomarker discovery services. High-throughput screening, single-cell analysis, and multi-omics approaches are expanding the scope of biomarker research, ensuring a more accurate understanding of disease mechanisms. Additionally, the rise of liquid biopsy techniques, which allow for non-invasive biomarker detection, is gaining traction in outsourced biomarker discovery services, offering new avenues for real-time disease monitoring and early detection. As these technologies continue to evolve, outsourcing partners are becoming increasingly indispensable for pharmaceutical companies seeking to accelerate biomarker-driven drug development.

What Market Trends Are Driving the Growth of Biomarker Discovery Outsourcing?

One of the most significant trends driving biomarker discovery outsourcing is the growing emphasis on personalized medicine. As healthcare shifts toward tailored treatment strategies, pharmaceutical firms are leveraging outsourcing services to develop biomarkers that enable precise patient stratification and targeted therapies. This trend is particularly evident in oncology, where biomarker-driven drug development is playing a pivotal role in immunotherapy and targeted cancer treatments. Another major trend is the increasing collaboration between pharmaceutical companies and contract research organizations to accelerate drug discovery timelines. Outsourcing biomarker discovery allows drug developers to access cutting-edge technologies and specialized expertise without the need for extensive in-house investments. Additionally, regulatory agencies such as the FDA and EMA are placing greater emphasis on biomarker-driven drug approvals, incentivizing pharmaceutical firms to outsource biomarker validation and compliance support. The rise of decentralized and virtual clinical trials is also reshaping the biomarker discovery landscape, as remote biomarker collection and AI-powered data analysis gain traction.

What Are the Key Growth Drivers for the Biomarker Discovery Outsourcing Market?

The growth in the Biomarker Discovery Outsourcing Services market is driven by several factors including the increasing complexity of biomarker research, rising demand for precision medicine, and advancements in AI-driven data analytics. The high costs associated with in-house biomarker discovery are prompting pharmaceutical companies to seek external partners that can provide cost-effective and efficient biomarker solutions. The globalization of clinical trials and the need for multi-regional biomarker validation studies are also contributing to market expansion, as outsourcing enables drug developers to conduct studies across diverse patient populations. Additionally, the integration of big data analytics and cloud-based platforms is streamlining biomarker discovery workflows, improving data interpretation, and enhancing clinical trial success rates. As the demand for biomarker-driven therapeutics continues to grow, outsourcing is expected to play an increasingly pivotal role in accelerating drug development and advancing personalized medicine.

SCOPE OF STUDY:

The report analyzes the Biomarker Discovery Outsourcing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers, Safety Biomarkers); Discovery Phase (Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase, Biomarker Selection Phase); Therapeutic Area (Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area, Other Therapeutic Areas); End-Use (Biotechnology Companies End-Use, Pharmaceutical Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • AB Sciex LLC
  • BioIVT LLC
  • Charles River Laboratories, Inc.
  • Creative Biolabs
  • Crown Bioscience Inc.
  • Discovery Life Sciences
  • Eurofins Scientific SE
  • Evotec SE
  • Laboratory Corporation of America Holdings
  • Metabolon, Inc.
  • REPROCELL Inc.
  • Sino Biological, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biomarker Discovery Outsourcing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increased Complexity of Early Drug Discovery Pipelines Throws the Spotlight on Outsourced Biomarker Discovery Services
    • Expansion of Multi-Omics Platforms Drives Demand for Integrated Discovery and Validation Capabilities
    • Rising Use of AI in Biomarker Pattern Recognition Spurs Adoption of Advanced Computational Discovery Models
    • OEM Preference for Targeted and Predictive Biomarkers Strengthens Value Proposition of External Discovery Experts
    • Growth in Stratified Medicine and Early Disease Detection Fuels Need for Rapid Biomarker Identification Workflows
    • Integration of Mass Spectrometry, NGS, and Proteomics Enhances Analytical Sophistication in Discovery Outsourcing
    • Use of Patient-Derived Organoids and Cell Lines Expands Biological Relevance in Biomarker Screening
    • Rising Investment in Biomarker Discovery for Neurodegenerative and Autoimmune Diseases Spurs Outsourced R&D
    • Development of Microbiome and Metabolome Biomarkers Broadens Scope of Discovery Services
    • OEM Collaboration With Biobanks and Data Lakes Strengthens Sample Access for Exploratory Biomarker Projects
    • Emergence of Digital Biomarkers and Sensor-Based Platforms Drives Demand for Cross-Functional Discovery Teams
    • Growth in Oncology Pipeline Assets Promotes Early Identification of Prognostic and Predictive Biomarkers
    • OEM Interest in Preclinical Biomarker Panels and Translational Research Accelerates CRO Engagement
    • Increased Emphasis on Early-Stage Regulatory Consultation Promotes Use of Validated Discovery Frameworks
    • Expansion of Biomarker IP Portfolios Encourages Outsourcing of Discovery With Tech Transfer Rights
    • Rising Use of Multi-Site and Cross-Population Biomarker Validation Strengthens Role of Global Discovery CROs
    • OEM Demand for Biomarker Qualification and Assay Transferability Fuels Service Model Integration
    • Emergence of High-Throughput Single-Cell Technologies Spurs Innovation in Functional Biomarker Screening
    • Cost and Timeline Pressure in Drug Discovery Enhances Outsourcing of Specialized Biomarker Tasks
    • Academic and Biotech Alliances With CROs Promote Public-Private Biomarker Discovery Ecosystems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biomarker Discovery Outsourcing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Surrogate Endpoints by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Surrogate Endpoints by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Predictive Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Predictive Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Prognostic Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Prognostic Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Safety Biomarkers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Safety Biomarkers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oncology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cardiology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cardiology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Neurology Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Neurology Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Autoimmune Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Autoimmune Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Biomarker Identification Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Biomarker Identification Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Biomarker Validation Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Biomarker Validation Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Biomarker Profiling Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Biomarker Profiling Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Biomarker Panel Development Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Biomarker Panel Development Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Biomarker Selection Phase by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Biomarker Selection Phase by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 42: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • CANADA
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • JAPAN
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 58: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 60: Japan Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Japan 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • CHINA
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 66: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • EUROPE
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 76: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 78: Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • FRANCE
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 84: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • GERMANY
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 94: Germany Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Germany 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • ITALY
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 100: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 102: Italy Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Italy 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • UNITED KINGDOM
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 104: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 108: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Rest of Europe 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Biomarker Discovery Outsourcing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Asia-Pacific 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Type - Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Type - Percentage Breakdown of Value Sales for Surrogate Endpoints, Predictive Biomarkers, Prognostic Biomarkers and Safety Biomarkers for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Therapeutic Area - Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology Therapeutic Area, Cardiology Therapeutic Area, Neurology Therapeutic Area, Autoimmune Diseases Therapeutic Area and Other Therapeutic Areas for the Years 2025 & 2030
    • TABLE 132: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by End-Use - Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by End-Use - Percentage Breakdown of Value Sales for Biotechnology Companies End-Use, Pharmaceutical Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Biomarker Discovery Outsourcing Services by Discovery Phase - Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World 6-Year Perspective for Biomarker Discovery Outsourcing Services by Discovery Phase - Percentage Breakdown of Value Sales for Biomarker Identification Phase, Biomarker Validation Phase, Biomarker Profiling Phase, Biomarker Panel Development Phase and Biomarker Selection Phase for the Years 2025 & 2030

IV. COMPETITION